PMID- 28903924
OWN - NLM
STAT- MEDLINE
DCOM- 20171127
LR  - 20190116
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 358
DP  - 2017 Sep 13
TI  - Multivariate and network meta-analysis of multiple outcomes and multiple
      treatments: rationale, concepts, and examples.
PG  - j3932
LID - 10.1136/bmj.j3932 [doi]
FAU - Riley, Richard D
AU  - Riley RD
AD  - Research Institute for Primary Care and Health Sciences, Keele University,
      Staffordshire, UK r.riley@keele.ac.uk.
FAU - Jackson, Dan
AU  - Jackson D
AD  - MRC Biostatistics Unit, Cambridge, UK.
FAU - Salanti, Georgia
AU  - Salanti G
AD  - Institute of Social and Preventive Medicine, University of Bern, Switzerland.
AD  - University of Ioannina School of Medicine, Ioannina, Greece.
FAU - Burke, Danielle L
AU  - Burke DL
AD  - Research Institute for Primary Care and Health Sciences, Keele University,
      Staffordshire, UK.
FAU - Price, Malcolm
AU  - Price M
AD  - Institute of Applied Health Research, University of Birmingham, UK.
FAU - Kirkham, Jamie
AU  - Kirkham J
AD  - MRC North West Hub for Trials Methodology Research, Department of Biostatistics, 
      University of Liverpool, Liverpool, UK.
FAU - White, Ian R
AU  - White IR
AD  - MRC Biostatistics Unit, Cambridge, UK.
AD  - MRC Clinical Trials Unit at UCL, London, UK.
LA  - eng
GR  - MC_U105260558/Medical Research Council/United Kingdom
GR  - MC_UP_0801/1/Medical Research Council/United Kingdom
GR  - MR/J013595/1/Medical Research Council/United Kingdom
GR  - MR/J013595/2/Medical Research Council/United Kingdom
PT  - Journal Article
DEP - 20170913
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
RN  - 0 (Antineoplastic Agents, Hormonal)
RN  - 4G7DS2Q64Y (Progesterone)
RN  - 9001-32-5 (Fibrinogen)
SB  - AIM
SB  - IM
MH  - Antineoplastic Agents, Hormonal/therapeutic use
MH  - Cardiovascular Diseases/blood/epidemiology
MH  - Clinical Trials as Topic
MH  - Endometrial Neoplasms/drug therapy
MH  - Female
MH  - Fibrinogen/metabolism
MH  - Humans
MH  - Multivariate Analysis
MH  - Myocardial Infarction/drug therapy
MH  - *Network Meta-Analysis
MH  - Progesterone/therapeutic use
MH  - Thrombolytic Therapy
MH  - Treatment Outcome
PMC - PMC5596393
COIS- Competing interests: We have read and understood the BMJ policy on declaration of
      interests and declare: none.
EDAT- 2017/09/15 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/09/15 06:00
PHST- 2017/09/15 06:00 [entrez]
PHST- 2017/09/15 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
AID - 10.1136/bmj.j3932 [doi]
PST - epublish
SO  - BMJ. 2017 Sep 13;358:j3932. doi: 10.1136/bmj.j3932.